{
    "nct_id": "NCT03116997",
    "official_title": "Randomized Controlled Assessor Blinded Clinical Trial of Sugammadex Versus Neostigmine /Glycopyrrolate for Reversal of Rocuronium Induced Neuromuscular Blockade: Time to Discharge From Post Anesthesia Care Unit and Patient Satisfaction With Recovery",
    "inclusion_criteria": "* Adult patients age 18 years of age or greater who are capable of giving consent\n* Undergoing surgical procedures of expected length 6 </= hours requiring NMB\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnancy\n* History of documented anaphylaxis or contraindication to any of the study medications\n* Active coronary disease with a positive cardiac stress test\n* History of severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 < 50% of predicted\n* Serum Creatinine >/= 2.0 mg/dL\n* Severe hepatic dysfunction accompanied by coagulopathy\n\n  * Definition:\n  * Known liver Disease AND\n  * INR > 1.5 (except for patients on anticoagulants) AND\n  * Platelet count <100,00/ul without other obvious cause\n* Chronic sustained release opioid for > 2 weeks duration pre op (in the 30 days prior to surgery)\n* Use of toremifene\n* Significant cognitive impairment or documented psychologic impairment\n* Myasthenia gravis or other neuromuscular disease\n* Patients who are not eligible for standard anesthetic induction, eg, those needing rapid sequence induction or awake fiberoptic bronchial intubation.\n* American Society of Anesthesiologists (ASA) Status > 3",
    "miscellaneous_criteria": ""
}